Evidence map›Paper›PMID 37217526›Full record

ArticleScientific reports2023

Novel genetically engineered mouse models for clear cell renal cell carcinoma.

Johannes C van der Mijn, Kristian B Laursen, Leiping Fu, Francesca Khani, Lukas E Dow, Dawid G Nowak, Qiuying Chen, Steven S Gross, David M Nanus, Lorraine J Gudas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Johannes C van der Mijn *Department of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Kristian B Laursen *Department of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Leiping FuDepartment of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Francesca KhaniDepartment of Pathology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.
Lukas E DowDepartment of Biochemistry, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.
Dawid G NowakDepartment of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Qiuying ChenDepartment of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Steven S GrossDepartment of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
David M NanusDivision of Hematology/Oncology, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.
Lorraine J GudasDepartment of Pharmacology, New York Presbyterian Hospital, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA. ljgudas@med.cornell.edu.
New York Hospital Queens · USNewYork–Presbyterian Hospital · USWeill Cornell Medicine · USCornell University · USPresbyterian Hospital · US

Funding

Gene Nutrient Interactions in Kidney FunctionR01DK113088 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2018 to 2025
$3.7M
Instrumentation for Ultra-high Resolution MALDI-FT-ICR Imaging CoreS10OD023652 · OD · WEILL MEDICAL COLL OF CORNELL UNIV · PI GROSS, STEVEN S · 2017 to 2017
$1.2M
NIDDK NIH HHS R01 DK113088NIH HHS S10 OD023652
6 · The paper itself

Abstract

Genetically engineered mouse models (GEMMs) are important immunocompetent models for research into the roles of individual genes in cancer and the development of novel therapies. Here we use inducible CRISPR-Cas9 systems to develop two GEMMs which aim to model the extensive chromosome p3 deletion frequently observed in clear cell renal cell carcinoma (ccRCC). We cloned paired guide RNAs targeting early exons of Bap1, Pbrm1, and Setd2 in a construct containing a Cas9

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsHumansInfantMaleMiceMutationPromoter Regions, GeneticTumor Suppressor ProteinsTumor Suppressor Proteins

Identifiers

PMID37217526
PMCPMC10203127
OpenAlexW4377294711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.